Cori Clinical, an AI platform for clinical trials, has raised $4 million in Seed funding. The round was led by Breega, with participation from Enzo, Heartfelt, Together Ventures, and Bynd.
The company is using AI to address the slow and disconnected processes involved in planning and setting up clinical trials. Its platform aims to bring different sources of information together and make clinical trial preparation more efficient.
Jorn Jansen Schoonhoven, co-founder and CEO of Cori Clinical, said, “Clinical trials are built through a series of interconnected decisions about how a study should be designed and run. Today, much of the knowledge and precedent behind those decisions is scattered across previous trials, siloed teams, internal systems and separate documents. Cori brings that intelligence together into a living blueprint, so teams can make better-informed decisions before avoidable problems become delays, so the science never waits on the process.”
Cori was founded by Jorn Jansen Schoonhoven, who serves as CEO, and Patricio Fernández, who is CTO. The company has built an AI workspace that combines information from an organisation’s past clinical trials with data from trial registries, regulatory guidelines, and public sources. These include information from the US FDA, the UK MHRA, and the European Medicines Agency.
The platform helps clinical teams turn an initial trial idea into a complete trial protocol, regulatory submission documents, and operational plans. Instead of creating separate documents, Cori builds what it calls a “living blueprint” that can be updated as the trial develops.
Cori’s platform also helps teams compare new trial designs with previous experience and outside research. It can highlight potential risks and connect decisions about the study design with budgets, timelines, and operational plans.
The company says its technology can reduce repeated work, unnecessary changes, costs, and delays during trial planning. Based on its internal analysis, Cori estimates that its approach could cut average clinical trial setup costs by at least 33%. In an internal test, its AI reviewer identified 82% of protocol errors that were considered avoidable.
Cori is already working with two of the world’s five largest clinical research organisations (CROs). Its customers also include Erasmus MC, a university hospital and academic medical centre in Rotterdam, where Cori has supported two clinical trials focused on neurosurgery and neuro-oncology.
